

Development of highly selective STAT3 allosteric inhibitors as oral IBD therapies to overcome the limitations of existing treatments

Huchembio Co., Ltd.



IMMUNOLOGY	Candidate
Product Type	Small molecules
Indication	IBD(1 st), SLE/Lupus nephritis, Osteoarthritis, Neuroinflammation(BBB)
Target	STAT3
MoA(Mechanism of Action)	Selective STAT3 allosteric inhibitor
Competitiveness	• IL-23 Inhibitor : Skyrizi (risankizumab), Omvoh (mirikizumab). Tremfya (guselkumab) • JAK Inhibitor : Rinvoq (Upadacitinib), Xeljanz (Tofacitinib), Sotyktu(deucravacitinib)
Development Stage	Candidate
Route of Administration	Oral

Any unauthorized distribution or reproduction of this material is strictly prohibited.